Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Non-Current Deffered Revenue (2016 - 2018)

Historic Non-Current Deffered Revenue for Anaptysbio (ANAB) over the last 4 years, with Q4 2018 value amounting to $171000.0.

  • Anaptysbio's Non-Current Deffered Revenue rose 2214.29% to $171000.0 in Q4 2018 from the same period last year, while for Dec 2018 it was $171000.0, marking a year-over-year increase of 2214.29%. This contributed to the annual value of $171000.0 for FY2018, which is 2214.29% up from last year.
  • Latest data reveals that Anaptysbio reported Non-Current Deffered Revenue of $171000.0 as of Q4 2018, which was up 2214.29% from $162000.0 recorded in Q3 2018.
  • Anaptysbio's 5-year Non-Current Deffered Revenue high stood at $171000.0 for Q4 2018, and its period low was $115000.0 during Q4 2015.
  • In the last 4 years, Anaptysbio's Non-Current Deffered Revenue had a median value of $150500.0 in 2016 and averaged $147900.0.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first surged by 3391.3% in 2016, then tumbled by 2380.95% in 2018.
  • Quarter analysis of 4 years shows Anaptysbio's Non-Current Deffered Revenue stood at $115000.0 in 2015, then surged by 33.91% to $154000.0 in 2016, then dropped by 9.09% to $140000.0 in 2017, then grew by 22.14% to $171000.0 in 2018.
  • Its last three reported values are $171000.0 in Q4 2018, $162000.0 for Q3 2018, and $128000.0 during Q2 2018.